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ABSTRACT 
The aim of this research was to develop and evaluate liquisolid compacts of Ezetimibe a bcs class II drug. The series of formulations containing 
Ezetimibe drug were formulated by using aerosil a colloidal silicone dioxide and avicel PH microcrystalline cellulose in different ratios by using 
suitable solvent. Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the choice of the best 
non volatile liquid to dissolve Ezetimibe. On the basis of the solubility data PG was chosen as a good solvent for the Ezetimibe. Ezetimibe was 
dissolved in solvent PG for the preparation of solution of drug. The coating and carrier materials transferred to the drug solution and added 5% 
of disintegrating agent (Croscarmellose) was mixed completely and the blend is compressed into compacts. Formulated compacts were 
evaluated for all post compression parameters and the in-vitro drug release study was carried out. All the formulations have shown a very good 
drug release in  15 min except compressibility problems due to higher812 loading factor of liquid vehicle for the formulations. The selected 
formulation F11 containing 30% of drug solution has  shown good drug release of 100.01% in 15  min compared to dissolution of  pure drug and 
marketed tablet which shown 45.5%  and 81.6 % respectively.No interactions were found  between drug and polymers in FITR as well as DSC. 
XRD of selected formulation shows that drug present in the formulation is in amorphous form. 
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INTRODUCTION  
The oral administration is the route of choice and is the very 
much preferred route for administration of drug due to more 
patient fulfillment (or) acceptance in the drug development. 
Because of some associated problems caused by this route of 
administration, this is complicated to achieve the plasma 
drugs concentrations. The drug solubility is a biggest 
problem and it is the most important to attain the required 
amount of drug into the blood.1 
The drugs have incomplete bioavailability which is less 
water soluble and having less dissolution rate. The challenge 
of slightly solubility of drug in water is to develop the 
solubilization and dissolution of drug. Various types of 
techniques that can be utilized to develop the solubilization 
of less water soluble and water insoluble active constituent, 
like reduction of particle size into microns, freeze drying, 
dispersion of drug into solubilising agent, using complex 
forming agents, co solvents, chemically modifications, 
adjusting pH, solubilization with surface active agents, Solid 
solution, encapsulation of drug in liquid form into the soft 
gelatin capsule, formation of salt. The techniques like these 
were introduced to develop the drug solubility and to boost 
the absorption of drug and drug bioavailability. The 
liquisolid compact is admissible fluidly and is a compressible 
powder form of liquid medicament. A liquid portion, which 
may be an oily liquid medicament, suspensions or solutions 
of poorly water soluble drug in an appropriate solvent 
vehicle of nonvolatile, is included in the carrier agent of 
porous nature. During the saturation point of carrier with 
solvent, formation of solvent layer takes place over the 
surface of particles which then get adsorbed fatly by the 
coating particles of fine nature. In this way, a clearly dry easy 
flowing powder for compressibility is obtained. The 
concentrations of carrier, coating material, disintegrant, 
lubricant and glidant are optimized to obtain a non-stick 
readily compressible mixture. These techniques were 
introduced to progress the drug solubility molecule also to 
enhancement of absorption and also drug bioavailability. The 
method of solid dispersion is significant for the enhancement 
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of drug solubilization, its wetting property, and to boost the 
drug solubility and bioavailability. In order to solve all such 
type of problems, the “Liquisolid Technique "was developed 
which may called as the Technology of Powder solution 
Hence main objectives of this present study were to carry 
out the solubility enhancement technique for the BCS class II 
drugs by using the liquisolid compact technique.2 
MATERIALS AND METHODS 
Materials: Ezetimibe Hcl is received as gift sample from 
Glenmark pharma Mumbai, colloidal silicone dioxide (Aerosil 
200), Microcrystalline cellulose (Avicel PH 101) are received 
from Microlabs Bangalore and solvents like Propylene 
Glycol, PEG solvents are used of laboratory grades purchased 
from SD fine chemicals Mumbai. All other solvents and 
reagents were used as analytical grade. 
 
Table 1 Formulation of liquisolid compacts of Ezetimibe 
Liquisolid 
system* 
Drug concentration 
in PG  (% w/w) 
R R=Q/q Lf Lf=W/Q 
Avicel PH 102 
Q = W/Lf 
Aerosil 200 
q=Q/R 
Formulation 
wt  (mg)  
 
       
 F1  
10% (100 mg) 
 
 
5 0.50 200 40 275 
F2 10 0.40 250 30 320 
 
F3 20 0.33 300 20 365 
 
F4 30 0.28 350 18.3 405 
 
F5  
20%(50mg) 
 
 
5 0.50 100 20 145 
 
F6 10 0.33 150 15 195 
 
F7 20 0.25 200 10 245 
 
F8 30 0.20 250 8.3 295 
 
F9 
 
30%(33mg) 
 
5 0.33 100 20 145 
 
F10 10 0.22 150 15 195 
 
F11 20 0.16 200 10 245 
 
F12 30 0.13 250 8.3 295 
 
F13  
40%(25mg) 
 
 
5 0.27 90 18 130 
 
F14 10 0.25 100 10 135 
 
F15 20 0.22 110 5.5 140 
 
F16 30 0.20 120 4 150 
 
 
Determination of solubility of Ezetimibe drug:  
Solubility studies were performed in propylene glycol and 
polyethylene glycol (PEG-200, 400, 600) for the choice of the 
best non volatile liquid to dissolve Ezetimibe. Saturated 
solutions have been developed by the addition of surplus 
medications to solvent vehicles and stirring in a shaker 
incubator for 48 hours at 25 º C ± 1 º C. Following this stage 
the filtration was done  by a filter of 0.45 µm Miilpore, by  
diluting using distilled water and done analysis by a the help  
of UV visual spectral in the wavelength of 232 nm against the 
blank in a solvent of non volatile in nature is the most 
significant  quality of liquisolid system. The drug 
solubilization helps in the molecular dispersion in non 
volatile solvents like that may get improvement in the rate of 
dilution. On the basis of the solubility data PG was chosen as 
a good solvent for the Ezetimibe. 
Preparation of liquisolid compacts: 
Ezetimibe was dissolved without changing solvent PG for the 
preparation of solution of drug. The combination of coating 
and carrier materials transferred Avicel PH102 as carrier 
and colloidal silicon dioxide (Aerosil 200) as the coating 
adjuvant which was then added to the solvent and mixed in 
ceramic mortar to avoid over-trituratio and reduce particle 
size. The blend was done in three phases; in the first phase, 
the drugs are slowly mixed to get    even distribution of 
solvent medications. In the next stage, the blend was 
spreaded as a homogeneous coat on the surface and 
remained in position for few minutes of interval. In last 
phase addition of 5% of disintegrating agent 
(Croscarmellose) was done to the granules or powder and 
mixed completely. The last blend is compressed into 
compacts by using 12 mm punches of round flat type in 16 
station rotary tablet machine. 3 
Evaluation of liquisolid compacts 
Determining the drug solubility   
Solubility studies had been conducted to choose the higher 
solubilization of the pure drug model in solvents like 
nonvolatile nature, which includes drugs solubilized in 
various solvents of nonvolatile. The quantities of excess net 
drugs were added to non-volatile solvents, followed by a 
transfer of saturation solution to rotary transformers for 48 
hours at 25oC under continuous vibration. After a period of 
48 hours the saturated solution is filtered by using a filter 
like Millipore of 0.45 μm and analyzed. 
Solubility studies were performed in the solvents propylene 
glycol and polyethylene glycol (PEG-200, 400, 600) to select 
the best non-volatile solvent to dissolve ezetimibe. Saturated 
solutions have been developed by the addition of excess 
medications to vehicles and stirring in a shaker incubator for 
48 hours at 25 º C ± 1 º C. After this period the solutions 
were filtered through a filter of 0.45 µm Millipore, diluted 
with distilled water and distributed by a double radius of 
visible UV spectral spectrum in the wavelength of 232 nm.  
Determination of angle of slide 
Many standard liquid compounds/powder mixtures 
containing 10 grams of carrier or coating material are 
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prepared with increasing amounts of liquid vehicles. To 
measure the angle of slide, the liquid mixtures/powder of 
Ezetimibe was placed on polished metal plates, and then 
gradually imbalanced until the liquid/powder was slided on 
the verge of slipping. The angle that is formed between the 
panel and the horizontal surface is defined as the angle of the 
slide.  
Calculation of the loading factor: 
In the liquisolid system, the microcrystalline cellulose and 
aerosol could only keep definite amount of solvent by the 
maintenance of the satisfactory flow also compressibility 
characteristics according to the ratio used. The ratio of 
powder found in was R where  of powder or 
granules are stated like fraction of carrier adjuvant (q) and 
the coating adjuvant materials (q) of the system. It is 
possible to set up the "Ezetimibe" system, which is 
transferable with an acceptable flow and the possibility of 
compression if it does not exceed the maximum fluid limit in 
the carrier's material. This nature of  liquid is called a liquid 
or solvent loading factor (LF) and  may be stated as the 
weight fraction of solvent medicine (W) and the adjuvant 
carrier (q) in the method  where LF = w/q. For computation 
of the liquid or solvenht load factor, solvents (liquid drugs 
without medication) with nonvolatile have been included to 
10gm of carrier materials and collected for 1 minute then in 
this material addition of coating material done and mixed. 
The formulations are designed for Ezetimibe liquisolid 
systems according to the mathematical model described by 
Spireas et al. According to the theories of liquisolid tablets, 
the powder carrier and coating agents can only hold definite 
amounts of solvents and maintains an acceptable flow and 
compressible force. The fraction of powder in ratio R is 
known as 
R = Q/q ——— (1) 
 Where R is the fraction of carrier weight (Q) and (q) of the 
coating material found in the formulations. The liquid load 
factor (LF) is defined as the weight fraction of the liquid drug 
(W) to the weight of the carrier (Q) in the system, which 
must be present in the flowing system and the 
compressibility. 
LF = W/Q ——— (2) 
LF = W/Q ——— (2) 
The ability to flow liquid retention (θ value) of powder 
absorbent material was used to calculate the required 
quantities of components. Therefore, the powder rates R and 
the liquid load factor LF of the formulations are related to 
the following way 
Loading factor = Φ C A + Φ CO * 1 / R. 
W = wt. of liquid drug, Q = wt. of carrier material 
Q = W/LF-(4) q = Q/R-(5)  
Where, Q is carrier agent and q is the coating agent.4 
Evaluation of Ezetimibe Liquisolid tablets (post 
compression parameter) 
The compression parameters of the Ezetimibe Liquisolid 
tablets are as follows. 
Tablets Size and shape: 
The size of tablets and tablets shapes can be explained as 
dimensions watched and controlled. It is found by the 
machine throughout the process of compression. 
Determination of Moisture of Granules: 
The granules or powders must have enough strength to 
resist normal process during handle of mixture and 
incorporation processes without production of big amount of 
fine dust. In some size decreasing process throughout the 
process of condense in the tablets is useful to represent the 
areas of the fresh surfaces required for best possible link to  
put so the dampness content is the very vital thing for fine 
medicinal products. 
Weight Variation Test:  
As per the USP the test for tablets weight variations test of 
the tablets Ezetimibe Liquisolid is made by weighing 20 
compacts independently by calculated common weights and 
compared the weight of individual tablet on mean weight. 
The variation in weights of tablets in test is denominated by 
percentage. The formula used for same weight variation test 
= (iw-aw)/aw X 100% where, iw = Individual or single 
weight of tablet. aw = average or mean  weight of tablet. 
According to USP the tablet comply with the tests if no extra 
than 2 out of  single weights diverge as of the mean mass by 
additional than the proportion divergence as shown in 
table.5 
Drug content uniformity:  
Standard preparation: About 20 mg of Ezetimibe was 
weighed accurately and shift to a flask of 50 ml. and dissolve 
then dilute and fill up to the volume with the Phosphate 
solution 7.4 pH and mixed. 
Preparation of sample solution: Five tablets were taken 
powdered and weighed into powder. The powder equal to 20 
mg is taken by weighing accurately. Drug Ezetimibe powder 
was transferred to a  flask of 50 ml and made to dissolve in a 
7.4 pH phosphate buffer. Sonication is done by keeping for 
30 minutes and filtered using membrane filter 0.45. It is then 
dissolved and diluted to the mark. The absorption of both 
after the appropriate dilutions was measured in a UV-visible 
spectrophotometer at 232 nm of standard preparation and 
the preparation of the sample at 7.4 pH phosphate solutions. 
The repetition of method was done for 3 times.   
Thickness: The tablet thickness of individual tablets was 
found with a sliding caliper scale of 5 or 10 tablets, where 
their total thickness was measured. The thickness of the 
tablet must be checked within a variation of ± 5% of a 
standard expressed in mm. 
Hardness Test: 
For this test tablet hardness tester, Monsanto hardness 
equipment is used to evaluate the hardness of tablet was 
used. The equipment contains a drum and a compressor 
spring which is held in between two divers. The piston is 
located to make contact with the tablet and receives reading 
at zero level. The piston which is upper side is moved with 
force in opposition to a spring by rotating a thread lock till 
the tablet breaks. When the compression of spring is done, 
an indicator reads alongside a meter in the drum to point out 
strength. The force of the break is noted in a k.g. Ten 
Ezetimibe liquisolid compacts are compressed and measured 
their hardness and the permissible range in between 4-6 kg 
(40-60 N) if not or else noted. 
Friability test: The test for Friability of tablets can find 
experimentally by Roche Friabilator. To test weight of 
twenty Ezetimibe liquisolid compacts are taken and kept in 
the Friabilator and then rotated at 25 Rotations per minute 
until 240 seconds. The tablet weight is noted again by 
dusting. The variation of two weights in tablets is noted to 
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compute the friability and the reading and is noted. This was 
found by using the formula: 
 
Where, IW = initial weight of compacts   FW = final weight of 
compacts. As per USP the compacts that loss is lesser than 
0.5% to 1% (after 100 rotations) of their weights are usually 
considered as satisfactory. 
Disintegration test: 
USP devices containing 6 glass or plastic tubes which are 3 
inches in length, open at the top, and covered by 10 no. net 
screen towards the base end of the basket stand apparatus. 
For  checking  the disintegrate time, a Ezetimibe liquisolid 
compact  is kept on every tube and the set of  basket is 
placed in a specific media at 37 ± 2 ° C, as the compacts 
leftovers 2.5 cm under the liquid surface in the movement 
towards ascending and descending is no nearer than 2.5 
centimeters from the base of the container. A model machine 
device is utilized to move the basket assemble which 
contains the tablets top and bottom throughout the space of 
5 to 6 cm. At a occurrence of 28 to 32 revolutions per minute. 
Plastic discs of perforated may be used in the study. The 
compacts are kept at the top of s and transmit a rough stroke 
on the tablets. Discs may be or may not be necessary or 
provide additional sensitivity to the study, but these are 
helpful for floating of compacts or tablets. Function the 
device for the specific time (900seconds for compacts of un 
coated, if not or else acceptable and permitted) 
The compacts comply as per the test if the compacts are 
dissolved, and all drug particles pass through the mesh at the 
specified time. If filtrate remains, it should have a soft mass 
without a clearly stable nucleus. The compacts   comply with 
the study as per the USP, if all the compacts have been fully 
dissolved. If the 1 or 2 compacts fail to dissolve totally, 
repeatation of the test should be done for 12 supplementary 
compacts. If the condition is not met then not lesser than 16 
of the 18 compacts are to be tested.6 
In vitro dissolution study of Ezetimibe Liquisolid 
compacts:  
Release of medications from Ezetimbe liquesolid tablets has 
been determined using the USP type II (paddle).   
Medium Solution: 0.45% SLS to 0.05 M acetic acetate 
solution, PH 4.5.Size: 500 ml. Temperature maintained 37°c 
± 0.5 °c . Speed of peddle 50 rpm. Solution of about 5ml has 
been withdrawn from the solution every time at suitable 
intervals of 10, 20, 30 and 45 minutes and is changed by 
replacing with fresh medium. After withdrawing the samples 
were filtered and analysis of the sample was made using a 
double beam of UV spectrophometer and analyzed using UV 
optical spectral scale in 232 nm. The drug concentration was 
commutated using a standard curve. 7 
 RESULT AND DISCUSSION 
Standard calibration curves of Ezetimibe drug in 0.1 N 
HCl: 
The calibrations curve of Ezetimibe drug was plotted by the 
absorbance v/s concentrations. The max of Ezetimibe drug 
in Acetate buffer pH 4.5 N was determined at max 232 nm. 
The values of absorbance are shown in table no-20 The 
standard calibrations curve of Ezetimibe is in the Beer's 
range between 5-30 g/ml . 
Determination of solubility of Ezetimibe drug: Solubility 
studies were performed in propylene glycol and 
polyethylene glycol (PEG-200, 400, 600) for the choice of the 
best non volatile liquid to dissolve Ezetimibe. Saturated 
solutions have been developed by the addition of surplus 
medications to solvent vehicles and stirring in a shaker 
incubator for 48 hours at 25 º C ± 1 º C. Following this stage 
the filtration was done  by a filter of 0.45 µm Miilpore, by  
diluting using distilled water and done analysis by a the help  
of UV visual spectral in the wavelength of 232 nm against the 
blank in a solvent of non volatile in nature is the most 
significant  quality of liquisolid system. The drug 
solubilization helps in the molecular dispersion in non 
volatile solvents like that may get improvement in the rate of 
dilution. On the basis of the solubility data  PG was chosen as 
a good solvent for the Ezetimibe. 
Determination of Angle of slide: 
Many standard solvent compounds or powder mixtures 
which contain 10 grams of carrier   or coating material are 
prepared with increasing amounts of liquid vehicles. To 
determine the angle of slide, the solvent or powder prepared 
from Ezetimibe kept on metal plate which is polished, and 
then slanted steadily until the liquid or powder mixture was 
get slided. The angle that is formed between the panel and 
the surface which is horizontal is stated as the angle of slide 
(h).  
The Angle of repose: 
The angle of repose of these powders is formed due to the 
effect of the inner particles of strong friction. The most 
cohesive molecules in nature have a higher angle of repose. 
Angle of repose smaller than thirty degrees shows good flow 
nature from a 40 degree angle and above shows poor flow. 
Formulations with a angle of repose superior than 40 are not 
satisfactory (F1-F10 and F13-f16 formulations) 
combinations, F11 and F12 shown 27 degrees, and 29 
degrees respectively, showed a good flow, but the F12 
formula necessary in a larger quantity of carrier adjuvant 
that improved the size of the compact to 295 mg. So the F11 
preparation was chosen for compression. 
Bulk density and tapped density:  
The acceptable range and values summarized in table 12 
indicate the values for all combinations from F1 to F16 in 
Ezetimibe formulations. This outcome helps to calculate the 
percentage of the powder compressibility within the 
acceptable limit. 
Carr’s Index: Based on these parameters, the F11 
formulation was chosen for further evaluation. Formulation 
F11 showed Carr index 10.12 and Hausner’s ratio of 1.11 to 
the total weight of the tablet of 245 mg. 
Post compression Parameters of Ezetimibe Liquisolid 
compacts: 
Hardness: The liquisolid system must have sufficient 
hardness to prevent breakage during manipulation, and also 
must be disintegrate. The formulation of F11 also showed a 
very good hardness of about 4 kg/cm 2.  
Thickness: The thickness values of F1 to F16 formulas are 
almost uniform in all formulas. 
Friability test: The friability results of the Ezetimibe 
liquisolid compacts have been found within the approved 
range (< 1%) and formulations from F1 to F16 and possess 
good mechanical strength. 
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Weight variation test: The percentage of tablets weight 
variations were found for the formulations F1 to F16. The 
values observed were within the acceptable limit. 
Drug content uniformity: The liquisolid tablets were 
evaluated to standardize the drug content by selecting ten 
compacts randomly. The compacts were powdered then 
weighed hundred mg of the powder then shifted in a 
volumetric flask of 100 ml, and the content of drug was 
estimated by spectrophotometrically at 232 nm (Indian 
Pharmacopeia) The drug content for compacts of all the 
formulations ranges in between 96.6-99.9%. The results 
indicates that the tablets active contents of all the 
preparations were found to be identical and contains right 
dose of the active ingredients. 
Disintegration time: The disintegration time of tablets are 
found to be 110 and 120 sec for formulation F11 and F12.For 
formulations F1 to F10 and formulations F13 to F16 was 
observed to be 345 to 380 sec. 
Dissolution study:Dissolution studies of all formulations 
from F1 to F16 were carried out in 0.45% SLS in 0.05 M 
Acetate Buffer, pH 4.5.No much difference is found in the 
solubility and rate of dissolution of all the formulations due 
to good solubility of drug in the solvent vehicle except 
compressibility problems due to higher loading factor of 
liquid vehicle for the formulations. All the formulations have 
shown a very good drug release in  15 min. 
The selected formulation F11 containing 30% of drug 
solution has  shown good drug release of 100.01% in 15  min 
compared to dissolution of  pure drug and marketed tablet 
which shown 45.5%  and 81.6 % respectively. The drug 
release data obtained for the formulation F11  along with 
pure drug and marketed tablet.8 
Drug-Excipient Interactions: 
FT-IR spectra of Ezetimibe LSC: 
FTIR spectroscopy was utilised for the analysis of the 
changes in structure and interaction possibilities of between 
the drug and Liquisolid compacts of Ezetimibe. The 
characteristic peaks of Ezetimibe was found to be 3200, 
2400, 1200,800 cm-1.  The FTIR spectrum of Liquisolid 
compacts of Ezetimibe showed its characteristic IR 
absorption peaks at 3300, 2400, 1100, 650 cm-1. These 
spectra observations revealed no any interactions among the 
carrier and drug used. 
Differential Scanning Calorimetry (DSC) of Ezetimibe 
LSC: 
The thermogram of DSC of pure Ezetimibe was showed a 
sharp peak of endotherm at 169.540C with respect to its 
melting point, indicates the crystal character of the drug. DSC 
thermograms of liquisolid compacts indicated broad peaks at 
187.560C, indicating a decreasing in the crystal nature of 
drug and its transform to amorphous form. A slight shift in 
the drug melting peaks indicating dissolution of drug in the 
non volatile liquid PEG 600 before reaching its fusion 
temperature. It was concluded that the presence of the drug 
affects the lattice energy of the crystalline polymer leading to 
shifting of the peak. The vanishing of drug peak in 
formulations into a liquisolid compacts  indicate  the 
absolute inhibition of all drug thermal characters certainly 
indicates the formation of an solid solution of amorphous. No 
other interactions were observed in between the drug and 
excipients. 
X-Ray Diffratrometry (XRD) of   Ezetimibe LSC: The X-ray 
diffractogram of the Ezetimibe Drug, Formulation F11 and 
Physical mixture. Ezetimibe shows sharp peaks at 16°, 17.5° 
and 19° and 19.5°. The nonexistence of distinguishing peak 
of Ezetimibe in liquisolid compacts shows that drug is 
completely transformed into amorphous or solubilized 
appearance. The nonexistence of crystal nature of the drug in 
the liquisolid compacts may be due to the effect of 
solubilisation in the solvent material which was absorbed in 
the carrier material and adsorbed on the coating materials. 
The liquisolid system and physical mixture preparations 
have the same diffracting pattern and found no other peaks. 
The amorphization or solubilization of Ezetimibe has 
increased the dissolution rate. 
Stability Study: The stability study was conducted for F11 
formulations stored in 40°C/75% RH for 30 days.  The 
various parameters were studied such as hardness, friability, 
drug contents uniformity, in vitro dissolution. There was not 
much variations observed in any parameters throughout 
study period of time. 9, 10 
CONCLUSION 
In this research, attempt was made to formulate liquisolid 
compacts by the use of Avicel PH and Aerosil 200, as carrier 
and coating material .Suitable solvent propylene glycol was 
selected based on solubility parameter and used as best 
solvent to dissolve Ezetimibe. Liquid loading factor was 
calculated based on the solubility property of drug into the 
solvent. The prepared liquisolid powders are subjected to 
precompression parameters and compressed into the 
compacts. The post compression parameters of compacts 
were evaluated   In vitro dissolution of compacts shown a 
very good drug release except compressibility problems in 
formulations with high liquid load factor other than 
Formulations F11 and F12 having low  liquid load factor. It 
was found that formulations F11 and F12 have shown a very 
good release and formulations.F11 when compared to the 
pure drug and marketed product has shown a good release 
and was selected as a final formulation based on the total 
weight of the tablets and subjected to the final 
characterization along with stability study. Thus this 
technology has shown a potential drug release for poor 
water soluble drugs and proves to be a potential approach 
for the enhancement of solubility of poor water soluble 
drugs thus enhancing the bio availability. 
 
 
 
 
 
 
 
 
 Marapur et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(2):321-329 
ISSN: 2250-1177                                                                                     [326]                                                                                     CODEN (USA): JDDTAO 
Table 2: Precompression parameters of liquisolid powders 
No 
Angle of 
Repose 
Bulk 
Density 
Tapped 
Density 
Carr’s 
Index 
Hausner’s 
Ratio 
F1  43 0.71 0.89 20.22 1.25 
F2 42 0.70 0.90 22.22 1.28 
F3 42 0.70 0.91 20.07 1.30 
F4 41 0.70 0.91 21.00 1.30 
F5 43 0.69 0.88 21.50 1.27 
F6 43 0.72 0.91 20.87 1.26 
F7 42 0.70 0.90 22.22 1.28 
F8 41 0.70 0.91 23.07 1.30 
F9 40 0.71 0.91 21.97 1.28 
F10 40 0.69 0.89 22.47 1.28 
F11 27 0.71 0.79 10.12 1.11 
F12 29 0.70 0.81 13.50 1.15 
F13 44 0.70 0.89 21.34 1.27 
F14 43 0.69 0.89 22.47 1.28 
F15 41 0.71 0.89 20.22 1.25 
F16 41 0.70 0.90 22.22 1.28 
 
Table 3: Post compression parameter of liquisolid compacts 
Formulation 
Code 
Hardness 
(kg/cm2) 
Weight 
Variation 
Friability 
% 
Thickness 
mm 
F1  
 
3.5 275±2.5 0.35 2.9 
F2 3.5 320±5.25 0.28 3.5 
F3 4.0 365±5.33 0.55 3.6 
F4 4.5 405±4.23 0.39 3.5 
F5 3.5 145±2.5 0.52 2.5 
F6 4.0 195±2.2 0.88 2.4 
F7 4.0 245±3.5 0.67 2.8 
F8 3.5 295±3.7 0.49 2.8 
F9 3.5 145±5.25 0.43 2.5 
F10 3.5 195±5.21 0.31 2.6 
F11 4.0 245±4.5 0.58 2.8 
F12 4.5 295±2.5 0.40 2.8 
F13 3.5 130±3.33 0.55 2.5 
F14 4.0 135±3.5 0.50 2.4 
F15 4.0 140±2.55 0.55 2.5 
F16 3.5 150±2.54 0.72 2.6 
 
Table 4:  Disintegration and drug content of liquisolid compacts 
Formulation 
Code 
Disintegration 
time (sec) 
Drug Content 
Uniformity (%) F1 360 96.6±0.25 
F2 350 97.7±0.85 
F3 345 98.4±0.66 
F4 350 99.3±0.56 
F5 390 98.5±0.50 
F6 370 96.70±0.55 
F7 375 97.0±0.45 
F8 365 99.9±0.75 
F9 355 98.1±0.85 
F10 350 99.5±0.80 
F11 280 98.0±0.90 
F12 310 99.2±0.25 
F13 380 97.0±0.10 
F14 375 98.5±0.25 
F15 370 97.3±0.50 
F16 380 98.0±0.76 
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Figure 1: In vitro Dissolution of formulation F11, marketed tablet and pure drug 
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Figure 3: FTIR of Ezetimibe Formulation 
 
Figure 4: DSC of Ezetimibe LSC formulation 
 Marapur et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(2):321-329 
ISSN: 2250-1177                                                                                     [328]                                                                                     CODEN (USA): JDDTAO 
 
Figure 5: DSC of Ezetimibe drug 
 
Figure 6: X-Ray Diffraction pattern of Ezetimibe 
 
Figure 7: X-Ray Diffraction pattern of Ezetimibe Liquisolid compacts 
 
Figure 8: X-Ray Diffraction pattern of Ezetimibe LSC formulation without drug 
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Table 5: Stability study of optimized formulation F 11 at 40 0C/75% RH 
F. Code 
After time 
(in days) 
Hardness 
(kg/cm
2
) 
DT 
time (sec) 
Thickness 
Drug content 
 
Friability 
% 
 
FV11 
10 4.2 280 2.8±.5 98.0±0.50 0.58 
20 4.10 275 2.8±.5 98.0±0.50 0.55 
30 4.0 285 2.8±.5 98.0±0.00 0.55 
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